Salta al contenuto principale
Passa alla visualizzazione normale.


Dose-finding study of oxaliplatin associated to capecitabinebased preoperative chemoradiotherapy in locally advanced rectal cancer

  • Autori: Bruera, G.; Di Staso, M.; Bonfili, P.; Galvano, A.; Manetta, R.; Coletti, G.; Vicentini, R.; Guadagni, S.; Ficorella, C.; Di Cesare, E.; Russo, A.; Ricevuto, E.
  • Anno di pubblicazione: 2018
  • Tipologia: Articolo in rivista (Articolo in rivista)
  • OA Link:


Introduction: Proper administration timing, dose-intensity, efficacy/toxicity ratio of oxaliplatin added to fluoropyrimidin should be improved to safely perform twodrugs intensive preoperative chemoradiotherapy in locally advanced rectal cancer (LARC). This dose-finding study investigated recommended oxaliplatin dose, safety of oxaliplatin/capecitabine regimen and preliminary activity. Methods: Schedule: oxaliplatin dose-levels, 35-40 mg/m2/week; capecitabine 825 mg/m2/ twice daily, radiotherapy on rectum/nodes, 50/45 Gy, 45 and 9 boost/45 Gy, in first 5 and subsequent patients, 5 days/week, respectively; for 5 weeks. Pathologic complete response (pCR) 10% was projected in order to positively affect clinical outcome. Results: Seventeen fit < 75 years patients enrolled: median age 60; youngelderly 4 (23%); T3/T4, 15/2, N0/N1/N2, 7/9/1. At first dose-level, no dose-limiting toxicity (DLT). At second, 2 DLT, G3 mucositis, G3 thrombocytopenia, in 2/6 patients (33%). Oxaliplatin recommended dose, 40 mg/m2/week. Cumulative G3-4 toxicities: mucositis 6%, thrombocytopenia 6%. Limiting toxicity syndromes 18%, 25% in young-elderly, all single site. Objective response rate intent-to-treat 94%. Sphinter preservation 87%, pCR 6%. After 17 months follow-up, progression-free survival and overall survival were not reached. Conclusions: Oxaliplatin can be safely added to preoperative capecitabinebased chemoradiotherapy at the recommended dose 40 mg/m2/week, in LARC, with promising pCR and high activity.